Compare LIVE & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIVE | CTSO |
|---|---|---|
| Founded | 1968 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3M | 49.7M |
| IPO Year | N/A | N/A |
| Metric | LIVE | CTSO |
|---|---|---|
| Price | $9.98 | $0.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 6.0K | ★ 123.7K |
| Earning Date | 12-11-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $443,794,000.00 | $36,979,520.00 |
| Revenue This Year | N/A | $11.93 |
| Revenue Next Year | N/A | $21.22 |
| P/E Ratio | $22.68 | ★ N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $6.25 | $0.60 |
| 52 Week High | $25.88 | $1.61 |
| Indicator | LIVE | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 45.97 |
| Support Level | $9.05 | $0.70 |
| Resistance Level | $12.49 | $0.85 |
| Average True Range (ATR) | 0.98 | 0.07 |
| MACD | 0.28 | 0.01 |
| Stochastic Oscillator | 47.36 | 49.56 |
Live Ventures Inc is a holding company for diversified businesses. It is focused on acquiring and operating profitable companies in various industries. The company operates in the business segments of Retail Entertainment which includes direct sales of entertainment and appliance products and services, Flooring Manufacturing, Steel Manufacturing, which includes the sale of steel plates, ground flat stock, and drill rods, and Corporate and Other. It derives key revenue from the Flooring Manufacturing segment which includes the manufacturing of carpets and rugs, yarn products, as well as a reseller of hard surface flooring products. Geographically the activities are carried out throughout the United States.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.